Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab

• Published in: Cancers 2022-11, Vol.14 (22), p.5659
• Main Authors: Yano, Yusuke, Ohno, Takaya, Komura, Kazumasa, Fukuokaya, Wataru, Uchimoto, Taizo, Adachi, Takahiro, Hirasawa, Yosuke, Hashimoto, Takeshi, Yoshizawa, Atsuhiko, Yamazaki, Shogo, Tokushige, Satoshi, Nishimura, Kazuki, Tsujino, Takuya, Nakamori, Keita, Yamamoto, Shutaro, Iwatani, Kosuke, Urabe, Fumihiko, Mori, Keiichiro, Yanagisawa, Takafumi, Tsuduki, Shunsuke, Takahara, Kiyoshi, Inamoto, Teruo, Miki, Jun, Kimura, Takahiro, Ohno, Yoshio, Shiroki, Ryoichi, Azuma, Haruhito
• Format: Article
• Language: English
• Subjects: Biomarkers; Blood platelets; C-reactive protein; Carcinoma, Renal cell; Cell survival; Clear cell-type renal cell carcinoma; Consortia; Disease control; Dosage and administration; Drug dosages; Drug therapy; Drug therapy, Combination; Health aspects; Hemoglobin; Immunotherapy; Inflammation; Ipilimumab; Kidney cancer; Lymphocytes; Medical prognosis; Metastases; Metastasis; Methods; Multivariate analysis; Neutrophils; Patient outcomes; Patients; Prognosis; Proteins; Renal cell carcinoma; Risk groups; Tomography; Tumors; Variance analysis
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14225659

Serum C-reactive protein (CRP) is known to be a biomarker for systemic inflammatory reactions. In the present study, we sought to measure the predictive value of serum CRP level for metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab and nivolumab using our real-world clinical dataset including non-clear cell RCC (nccRCC). The clinical record of patients who underwent the first-line ipilimumab plus nivolumab treatment for mRCC including ccRCC and nccRCC from 2018 to 2021 was retrospectively analyzed. All patients were diagnosed with either intermediate or poor-risk group defined by IMCD (international metastatic RCC database consortium). In total, 74 patients were involved. The median age was 68 years and 24 (32.4%) patients deceased during the follow-up. Forty-five (61%) and 29 (39%) patients were classified into intermediate and poor-risk groups. The one-year overall survival (OS) rate and objective response rate were 65% and 41% for all 74 mRCC patients, respectively. The receiver operating characteristic curve identified 1.0 mg/dL of serum CRP level as an ideal cut-off for predicting overall survival (OS). Serum CRP > 1.0 mg/dL and nccRCC were the independent predictors for OS in 74 mRCC patients. OS for patients with CRP > 1 mg/dL was significantly shorter than those with CRP < 1 mg/dL in both ccRCC (58 patient: p = 0.009) and nccRCC (16 patients: p = 0.008). The present study indicated that serum CRP level is a prognostic indicator for OS in both ccRCC and nccRCC patients treated with the first-line ipilimumab plus nivolumab treatment.